Update Prognostic Potency of Vascular Endothelial Growth Factor-A in the Acute Lymphoblastic Leukemia Landscape: A Meta-Analysis

IF 1.9 Q4 ONCOLOGY

Cancer reports Pub Date : 2025-09-13 DOI:10.1002/cnr2.70351

Mojtaba Aghaei, Mohammad Ali JalaliFar, Arshid Yousefi-Avarvand, Seyed Sobhan Bahreiny, Negin Karamali, Zahra Mansouri, Mahdi Amraei, Shaban Alizadeh, Najmaldin Saki, Mohammad-Navid Bastani, Tannaz Sakhavarz, Mohammad Ali Khaksar, Leila Goudarzimehr, Somaieh Mousavei, Ebrahim Babadi

{"title":"Update Prognostic Potency of Vascular Endothelial Growth Factor-A in the Acute Lymphoblastic Leukemia Landscape: A Meta-Analysis","authors":"Mojtaba Aghaei, Mohammad Ali JalaliFar, Arshid Yousefi-Avarvand, Seyed Sobhan Bahreiny, Negin Karamali, Zahra Mansouri, Mahdi Amraei, Shaban Alizadeh, Najmaldin Saki, Mohammad-Navid Bastani, Tannaz Sakhavarz, Mohammad Ali Khaksar, Leila Goudarzimehr, Somaieh Mousavei, Ebrahim Babadi","doi":"10.1002/cnr2.70351","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Vascular endothelial growth factor-A (VEGF-A), In combination with other pro-angiogenic factors, plays a pivotal role in angiogenesis and the pathogenesis of acute lymphoblastic leukemia (ALL).</p>\n </section>\n \n <section>\n \n <h3> Aims</h3>\n \n <p>This meta-analysis aims to evaluate the diagnostic value of VEGF-A and its prognostic relevance in the outcome of patients with ALL.</p>\n </section>\n \n <section>\n \n <h3> Methods and Results</h3>\n \n <p>A comprehensive literature search was conducted up to January 2025 across multiple databases. Standardized mean differences (SMDs) with 95% confidence intervals (CIs) were pooled using a random-effects model to quantify effect sizes. Subgroup analyses and meta-regression were employed to explore heterogeneity sources. Data extracted from 15 studies encompassing 674 patients with ALL demonstrated a significant correlation between elevated VEGF-A levels and unfavorable prognosis (SMD: 0.878; 95% CI: 0.276–1.479; <i>p</i> = 0.004). Notably, increased VEGF-A levels were particularly evident in pediatric patients older than 8 years (SMD: 0.758; 95% CI: 0.178–1.338; <i>p</i> = 0.010).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The results indicate that heightened VEGF-A expression is associated with poorer clinical outcomes in ALL, supporting its utility as a diagnostic and prognostic biomarker in this patient population.</p>\n </section>\n </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 9","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70351","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.70351","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Vascular endothelial growth factor-A (VEGF-A), In combination with other pro-angiogenic factors, plays a pivotal role in angiogenesis and the pathogenesis of acute lymphoblastic leukemia (ALL).

Aims

This meta-analysis aims to evaluate the diagnostic value of VEGF-A and its prognostic relevance in the outcome of patients with ALL.

Methods and Results

A comprehensive literature search was conducted up to January 2025 across multiple databases. Standardized mean differences (SMDs) with 95% confidence intervals (CIs) were pooled using a random-effects model to quantify effect sizes. Subgroup analyses and meta-regression were employed to explore heterogeneity sources. Data extracted from 15 studies encompassing 674 patients with ALL demonstrated a significant correlation between elevated VEGF-A levels and unfavorable prognosis (SMD: 0.878; 95% CI: 0.276–1.479; p = 0.004). Notably, increased VEGF-A levels were particularly evident in pediatric patients older than 8 years (SMD: 0.758; 95% CI: 0.178–1.338; p = 0.010).

Conclusion

The results indicate that heightened VEGF-A expression is associated with poorer clinical outcomes in ALL, supporting its utility as a diagnostic and prognostic biomarker in this patient population.

Abstract Image

查看原文本刊更多论文

血管内皮生长因子-A在急性淋巴细胞白血病预后中的最新效力：一项荟萃分析

血管内皮生长因子-a （VEGF-A）与其他促血管生成因子联合，在急性淋巴细胞白血病（ALL）的血管生成和发病过程中起关键作用。本荟萃分析旨在评估VEGF-A的诊断价值及其与ALL患者预后的相关性。方法与结果对截至2025年1月的多个数据库进行综合文献检索。采用随机效应模型对95%置信区间（ci）的标准化平均差异（SMDs）进行汇总，以量化效应大小。采用亚组分析和元回归分析探讨异质性来源。从包含674例ALL患者的15项研究中提取的数据显示，VEGF-A水平升高与不良预后之间存在显著相关性（SMD: 0.878; 95% CI: 0.276-1.479; p = 0.004）。值得注意的是，VEGF-A水平的升高在8岁以上的儿科患者中尤为明显（SMD: 0.758; 95% CI: 0.178-1.338; p = 0.010）。结论：VEGF-A表达升高与ALL患者较差的临床预后相关，支持其作为该患者群体诊断和预后生物标志物的实用性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊